Bernard Jasmin

GW501516, being developed to treat obesity, increases levels of the useful muscle protein utrophin in DMD mice

posted on September 21, 2009 - 9:00pm
An experimental drug being developed to treat obesity and high blood lipid (fat) levels also may have promise for the treatment of Duchenne (DMD) and Becker (BMD) muscular dystrophies, according to new, MDA-supported research from the University of Ottawa. MDA grantee Bernard Jasmin and graduate student Pedro Miura coordinated and led the study team, which published results online Sept. 10, 2009...
posted on July 1, 2007 - 10:32am
QUEST Vol. 14, No. 4
The underlying cause of Duchenne muscular dystrophy (DMD) can be any of a large number of mutations in the gene for the dystrophin protein. One strategy now being tested for overcoming this problem is gene therapy, the insertion of new dystrophin genes. Another is the transplantation of cells that give rise to muscle.